10x Genomics Launches Xenium Protein, Revolutionizing Spatial Biology with Integrated RNA and Protein Analysis

10x Genomics has launched Xenium Protein, a spatial biology platform that integrates RNA and protein analysis in one workflow, streamlining research and eliminating complex data integration. The platform is designed for cancer, immunology, and complex disease studies, with early adoption by companies like Sanofi. Xenium Protein complements existing RNA panels with ready-to-use protein subpanels, focusing on dozens of proteins involved in cell growth, signaling, and immune response. The platform's integration of RNA and protein analysis promises to expedite research timelines and accelerate therapeutic discoveries.

10x Genomics, Inc. (Nasdaq: TXG), a leading life science technology company, has announced the launch of Xenium Protein, a groundbreaking addition to its Xenium Spatial platform. This new product enables simultaneous RNA and protein detection within the same cell and tissue section in a single automated run, marking a significant advancement in spatial multiomics [1].

Xenium Protein is the first fully integrated spatial multiomic workflow for the Xenium platform, integrating RNA and protein analysis seamlessly. The platform features ready-to-use protein subpanels that work alongside RNA panels, focusing on dozens of proteins involved in cell growth, signaling, and immune response. This integration simplifies experimental design and shortens time to results, making it particularly valuable for studying cancer, immunology, and other complex diseases [2].

The launch of Xenium Protein underscores 10x Genomics' commitment to advancing spatial biology capabilities. By eliminating the need for separate technologies or sample sections, the platform enables researchers to gain more precise insights into biological systems. Early adoption by companies like Sanofi demonstrates the platform's potential to revolutionize research workflows and accelerate therapeutic discoveries [2].

The global availability of Xenium Protein indicates that 10x Genomics has successfully overcome manufacturing and distribution challenges for this complex product. The ready-to-use protein subpanels are strategically aligned with high-value research areas, positioning the platform for strong market acceptance among enterprise-level customers with substantial research budgets.

In conclusion, 10x Genomics' Xenium Protein represents a significant technological advancement in the field of spatial biology. Its integration of RNA and protein analysis promises to expedite research timelines and drive more precise therapeutic discoveries, making it a valuable tool for investors and financial professionals alike.

References:
[1] https://www.marketscreener.com/news/10x-genomics-launches-xenium-protein-advancing-spatial-biology-by-enabling-same-cell-rna-and-protein-analysis-302532774.html
[2] https://www.stocktitan.net/news/TXG/10x-genomics-launches-xenium-protein-advancing-spatial-biology-by-p1muh7vhyymr.html